(NASDAQ: CPRX) Catalyst Pharmaceuticals's forecast annual revenue growth rate of 5.3% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 105.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.22%.
Catalyst Pharmaceuticals's revenue in 2025 is $578,196,000.On average, 10 Wall Street analysts forecast CPRX's revenue for 2025 to be $70,464,442,343, with the lowest CPRX revenue forecast at $66,876,629,767, and the highest CPRX revenue forecast at $73,792,909,783. On average, 10 Wall Street analysts forecast CPRX's revenue for 2026 to be $76,398,652,388, with the lowest CPRX revenue forecast at $68,703,107,838, and the highest CPRX revenue forecast at $82,300,905,211.
In 2027, CPRX is forecast to generate $83,139,167,691 in revenue, with the lowest revenue forecast at $76,018,853,112 and the highest revenue forecast at $93,012,719,738.